Clearside Biomedical, Inc.

NasdaqGM:CLSD Stock Report

Market Cap: US$66.2m

Clearside Biomedical Management

Management criteria checks 2/4

Clearside Biomedical's CEO is George Lasezkay, appointed in Apr 2019, has a tenure of 5.67 years. total yearly compensation is $1.54M, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.5% of the company’s shares, worth $333.89K. The average tenure of the management team and the board of directors is 2.4 years and 5.5 years respectively.

Key information

George Lasezkay

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage35.6%
CEO tenure5.7yrs
CEO ownership0.5%
Management average tenure2.4yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

CEO Compensation Analysis

How has George Lasezkay's remuneration changed compared to Clearside Biomedical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$32m

Jun 30 2024n/an/a

-US$33m

Mar 31 2024n/an/a

-US$35m

Dec 31 2023US$2mUS$547k

-US$32m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$36m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$532k

-US$33m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

US$83k

Dec 31 2021US$2mUS$516k

US$376k

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$1mUS$503k

-US$18m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$385k

-US$31m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$82m

Dec 31 2018US$150kn/a

-US$83m

Sep 30 2018n/an/a

-US$78m

Jun 30 2018n/an/a

-US$72m

Mar 31 2018n/an/a

-US$65m

Dec 31 2017US$167kn/a

-US$59m

Compensation vs Market: George's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.

CEO

George Lasezkay (72 yo)

5.7yrs

Tenure

US$1,538,627

Compensation

Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...

Leadership Team

NamePositionTenureCompensationOwnership
George Lasezkay
President5.7yrsUS$1.54m0.50%
$ 333.9k
Charles Deignan
Chief Financial Officer12.9yrsUS$854.41k0.44%
$ 294.4k
Jenny Kobin
Head of Investor Relationsno datano datano data
Rick McElheny
Senior Vice President of Corporate Development & Alliance Management2.3yrsno datano data
Rafael Andino
Senior Vice President of Engineering & Manufacturing1.9yrsno datano data
Susan Coultas
Chief Clinical Officer2.5yrsno datano data
Ngai Hang Chong
Chief Medical Officerless than a yearno data0.13%
$ 87.2k
Leslie Zacks
Secretaryno datano datano data

2.4yrs

Average Tenure

59yo

Average Age

Experienced Management: CLSD's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
George Lasezkay
President7.3yrsUS$1.54m0.50%
$ 333.9k
Christy Shaffer
Independent Director12.9yrsUS$86.08k0.0058%
$ 3.8k
Benjamin Yerxa
Independent Director2.8yrsUS$88.58k0.024%
$ 15.7k
Jeffrey Edwards
Independent Director6.3yrsUS$88.58k0%
$ 0
Clay Thorp
Independent Director12.9yrsUS$96.08k0.053%
$ 35.3k
Carl Regillo
Member of Scientific Advisory Board4.7yrsno datano data
William Humphries
Independent Director12.9yrsUS$91.71k0.067%
$ 44.5k
David Boyer
Member of Scientific Advisory Board4.7yrsno datano data
Nancy Hutson
Independent Director4.7yrsUS$85.46k0.12%
$ 81.1k
Richard Croarkin
Independent Director8.8yrsUS$91.08k0%
$ 0
Anthony Gibney
Chairman of the Boardless than a yearno data0.13%
$ 87.2k
Arshad Khanani
Member of Scientific Advisory Board1.7yrsno datano data

5.5yrs

Average Tenure

63yo

Average Age

Experienced Board: CLSD's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniil GataulinChardan Capital Markets, LLC
Yi ChenH.C. Wainwright & Co.
Esther Lannie HongJanney Montgomery Scott LLC